Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03689192 · OUTCOME

Overall Survival

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors · Source last updated 2023-02-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
0 - 75 weeks

What was measured

Overall Survival (OS) defined as time from treatment initiation to death, will be described with use of Kaplan Meier curve.

Groups in this outcome

ARG1-18,19,20 Peptide Vaccine

One ARG1-vaccine every third week for 45 weeks. ARG1-18,19,20: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ARG1-18,19,20 Peptide Vaccine10

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
ARG1-18,19,20 Peptide Vaccine7.3Not reported4.518.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.5
        upper Limit
        18.8
        value
        7.3
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Overall Survival (OS) defined as time from treatment initiation to death, will be described with use of Kaplan Meier curve.
dispersion Type
95% Confidence Interval
groups
  1. description
    One ARG1-vaccine every third week for 45 weeks. ARG1-18,19,20: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
    id
    OG000
    title
    ARG1-18,19,20 Peptide Vaccine
param Type
MEDIAN
reporting Status
POSTED
time Frame
0 - 75 weeks
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice